N@N

Victhom completes enrollment for its Neurostep(R) clinical study

^{Published on 2009-06-09 13:06:13, Last Modified on 2009-06-09 13:07:26 - Market Wire}
 

 QUEBEC, June 9 /CNW Telbec/ - Victhom Human Bionics Inc., ("Victhom") (TSX: VHB), announced today that it had completed the enrollment of the ongoing human clinical study of its Neurostep(R) System at the end of March 2009. According to the Company, preliminary data shows promising results for the primary endpoints of the study, which are the safety and technical performance of the Neurostep(R) System. The Company expects the formal results of the clinical study to be available by the end of 2009. Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division, said: "We are pleased with the preliminary results coming out of the clinical study and with the feedback we have received from principal investigators and patients involved in this study. This clinical study will be the platform from which we will design and deploy the next North American study to be conducted in the United States and in Canada. Combined with the CE Mark approval received earlier this year, results from this study will allow Neurostream Technologies, our recently announced partnership with Otto Bock HealthCare GmbH, to increase market development activities in preparation for the European launch of the Neurostep(R) System." About the Neurostep(R) System Clinical Study The ongoing human clinical study on the Neurostep(R) System has two major objectives. The first is to evaluate the safety as well as the sensing and stimulation mechanisms of the system, and the second is to evaluate the efficacy of the Neurostep(R) in providing clinically measurable benefits, such as helping patients to walk faster and over longer distances. The Neurostep(R) System, a fully implantable investigational neuromodulation product designed to treat gait disorders (e.g., foot drop), is the first closed-loop system (CLS) product aimed at using the patients' own nervous system as the source for detection of intention to move and control their leg. Contrary to other systems that use surrogates such as external sensors, the Neurostep(R) detects intrinsic muscle activities and surface sensation events from the nerve signals delivered to the spine and brain. This information is then used as the trigger for intervention through neurostimulation, as needed, to complete function. Management Proxy Circular Victhom has released an amended version of its Management Proxy Circular in order to comply with the new requirements of the Autorité des machés financiers as specified in Appendix 51-102F6 concerning Executive Compensation. For this purpose, additional information regarding stock-option based compensation, more precisely, the fair value of options granted during 2008 as well as details on unexercised options at the end of 2008 and directors' compensation were added. The amended circular is available on SEDAR ([ www.sedar.com ]). About Victhom Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market. FORWARD-LOOKING STATEMENTS Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements. 

For further information: Normand Rivard, Acting President & CFO, Victhom Human Bionics Inc., (418) 872-5665, Fax: (418) 872-6926, [ normand.rivard@victhom.com ], [ www.victhom.com ]; Source: Victhom Human Bionics Inc.